M. Fedgchin

发表

Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant

W. Kraft, H. Greenberg, D. Dean, 2011, Cancer Chemotherapy and Pharmacology.

Vascular Effects of RWJ‐676070, a Selective Combined V1a/V2 Vasopressin Receptor Antagonist

M. Burnier, M. Maillard, B. Vogt, 2009, Clinical pharmacology and therapeutics.

Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression

Xiang Li, M. Furey, W. Drevets, 2022, The international journal of neuropsychopharmacology.

Fulranumab in Patients With Pain Associated With Postherpetic Neuralgia and Postraumatic Neuropathy

J. Thipphawong, M. E. Frustaci, G. Romano, 2016, The Clinical journal of pain.

Fulranumab for treatment of diabetic peripheral neuropathic pain

Hao Wang, S. Ness, Hao Wang, 2014, Neurology.

Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients

V. Cocquyt, D. Panebianco, P. Nygren, 2005, Cancer Chemotherapy and Pharmacology.

Approval of esketamine for treatment-resistant depression.

W. Drevets, Jaskaran Singh, M. Mathews, 2020, The lancet. Psychiatry.

Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.

W. Drevets, H. Manji, L. Alphs, 2018, The American journal of psychiatry.

Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.

W. Drevets, H. Manji, L. Alphs, 2019, Focus.

A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.

R. Shelton, M. Fava, W. Drevets, 2016, The American journal of psychiatry.

Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial

R. Shelton, M. Thase, W. Drevets, 2017, JAMA psychiatry.

Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study

W. Drevets, J. V. van Gerven, Jaskaran Singh, 2016, Psychopharmacology.

The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study

J. Verster, J. V. van Gerven, J. Garssen, 2017, Psychopharmacology.

Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)

M. Fava, M. Trivedi, W. Drevets, 2019, The international journal of neuropsychopharmacology.

Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study

Husseini Manji, Frank Wiegand, Wayne C. Drevets, 2016, Biological Psychiatry.

Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials

M. Furey, W. Drevets, D. Hibar, 2020, The international journal of neuropsychopharmacology.

Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants.

W. Drevets, Jaskaran Singh, M. Fedgchin, 2020, Advances in pharmacology.

Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies

W. Drevets, R. Doty, Jaskaran Singh, 2021, CNS Drugs.

Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With

W. Drevets, Jaskaran Singh, K. Cooper, 2020, Journal of affective disorders.

Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide : Results of a Double-Blind , Randomized , Placebo-Controlled Study

W. Drevets, L. Alphs, Jaskaran Singh, 2018 .

The effect of esketamine in patients with treatment‐resistant depression with and without comorbid anxiety symptoms or disorder

M. Trivedi, M. Thase, D. Ionescu, 2021, Depression and anxiety.

Comparability of blinded remote and site-based assessments of response to adjunctive esketamine or placebo nasal spray in patients with treatment resistant depression.

S. Targum, K. Cooper, M. Fedgchin, 2019, Journal of psychiatric research.

Efficacy and Safety of Intravenous Esketamine in Patients with Treatment-resistant Depression: A Double-blind, Double-randomization, Placebo-controlled Phase 2a Study

W. Drevets, P. Sienaert, H. Manji, 2013 .

Randomized, Double-Blind Study of Fixed-Dose Intranasal Esketamine Plus Oral Antidepressant vs. Active Control in Treatment-Resistant Depression

M. Fava, M. Trivedi, W. Drevets, 2019, Journal of Affective Disorders.